Skip to content

Study · In vitro (cells) · 2018

8 results

Interaction of Insulin-Like Growth Factor-Binding Protein 3 With Hyaluronan and Its Regulation by Humanin and CD44.

Muterspaugh R, Price D, Esckilsen D, McEachern S, Guthrie J, Heyl D, Evans HG

Biochemistry17 Sept 2018Cited by 19 (Europe PMC)

PMID30184438 (opens in a new tab)DOI10.1021/acs.biochem.8b00635 (opens in a new tab)PepBankPUB-30184438
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In the medium of A549 lung cancer cells, IGFBP-3 and humanin could be immunoprecipitated together as a complex.

    In plain wordsIn lung cancer cells, humanin and IGFBP-3 in the cell medium were found bound together.

    Peptide
    Humanin
    Outcome
    Not applicableHumanin-IGFBP-3 complex in cell medium
    Study

    n: not reported in source

    A549 lung cancer cells
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We show that IGFBP-3 and humanin in the medium of A549 lung cancer cells can immunoprecipitate in a complex.
  2. 02LabIn vitro (cells)Mechanism

    In cell medium, the fraction of IGFBP-3 that bound hyaluronan was not complexed with humanin.

    In plain wordsIn cells, the IGFBP-3 that bound hyaluronan was not bound to humanin.

    Peptide
    Humanin
    Outcome
    Not applicableComplex formation of hyaluronan-binding IGFBP-3 with humanin
    Study

    n: not reported in source

    A549 lung cancer cells
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, the fraction of IGFBP-3 in the medium that is able to bind HA was not complexed with humanin suggesting that HA binding to the 215-232 segment renders it inaccessible for binding to humanin.
  3. 03LabIn vitro (cells)Efficacy outcome

    In cell experiments, humanin reversed the cytotoxic effects of IGFBP-3 on cell viability.

    In plain wordsIn cells, humanin reversed the harm that IGFBP-3 did to cell survival.

    Peptide
    Humanin
    Outcome
    IncreaseCell viability with IGFBP-3 and humanin
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    while the cytotoxic effects of IGFBP-3 on cell viability were reversed by humanin
  4. 04LabIn vitro (cell-free)Activity measurement

    In cell-free binding assays, humanin bound the IGFBP-3 region 215-232 with higher affinity than hyaluronan.

    In plain wordsIn lab tests, humanin bound a segment of IGFBP-3 more tightly than hyaluronan did.

    Peptide
    Humanin
    Outcome
    Not applicableBinding affinity to IGFBP-3 region 215-232, humanin versus hyaluronan
    Study

    n: not reported in source

    Comparator
    Hyaluronan
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    found that HA binds with a weaker affinity to this region than does humanin.
  5. 05LabIn vitro (cell-free)Mechanism

    In cell-free assays, humanin and hyaluronan each could bind the IGFBP-3 segment, but not at the same time.

    In plain wordsIn lab tests, humanin or hyaluronan could bind the same IGFBP-3 segment, but not both together.

    Peptide
    Humanin
    Outcome
    Not applicableCompetition between humanin and hyaluronan for the IGFBP-3 segment
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Either HA or humanin could bind to this IGFBP-3 segment, but not simultaneously.
  6. 06LabIn vitro (cell-free)Mechanism

    In cell-free assays, the hyaluronan receptor CD44 had no effect on binding of humanin to IGFBP-3 or its peptide.

    In plain wordsIn lab tests, CD44 did not change how humanin bound to IGFBP-3.

    Peptide
    Humanin
    Outcome
    No significant changeEffect of CD44 on humanin binding to IGFBP-3
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but had no effect on binding of humanin to either IGFBP-3 or its peptide.
  7. 07LabIn vitro (cell-free)Mechanism

    In cell-free assays with hyaluronan and CD44, humanin bound and sequestered IGFBP-3 or its peptide, which enabled CD44 access to hyaluronan.

    In plain wordsIn lab tests, humanin held IGFBP-3 away from hyaluronan, so CD44 could reach hyaluronan.

    Peptide
    Humanin
    Outcome
    Not applicableHumanin sequestration of IGFBP-3 and access of CD44 to hyaluronan
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Upon incubation of HA with CD44 and either IGFBP-3 protein or peptide, humanin was effective at binding and sequestering IGFBP-3 or peptide, thereby enabling access of CD44 to HA.

Studies that did not test the peptide alone1

In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Humanin.

  1. 08LabNot a test of Humanin aloneIn vitro (cells)Efficacy outcome

    In cell experiments, blocking HA-CD44 interaction with an anti-CD44 antibody together with IGFBP-3 had no additive negative effect on cell viability.

    In plain wordsIn cells, adding a CD44 blocking antibody to IGFBP-3 did not lower cell survival further.

    Peptide
    Humanin
    Outcome
    No significant changeCell viability with IGFBP-3 plus anti-CD44 antibody
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    blocking HA-CD44 interaction with an anti-CD44 antibody in combination with IGFBP-3 did not have an additive negative effect on cell viability

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.